In a bold step toward global health justice, Ugandan biotech company DEI BioPharma has announced it will begin manufacturing ...

Utah biochemist Wesley Sundquist has achieved yet another milestone with the Food and Drug Administration approval of an antiviral drug for HIV prevention based on his findings.

It can take HIV symptoms years to appear—sometimes even longer—after infection. But within a month or two of HIV entering the body, 40% to 90% of people experience symptoms known as acute retroviral ...

The U.S. has approved the world's only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that ...

Yeztugo showed promising results in clinical trials. One study involving women in Africa reported 100% efficacy, with zero ...

The twice-yearly shot lenacapavir, sold under the name Yeztugo, reportedly nearly eliminated new HIV infections in studies of ...

The FDA has approved Yeztugo for PrEP to reduce the risk of sexually acquired HIV-1 in adults and adolescents weighing at least 35kg.

Gilead Sciences chairman and CEO Daniel O’Day joins 'Squawk Box' to discuss the FDA approval of the company's HIV prevention ...

The FDA has approved Yeztugo (lenacapvir), a twice-yearly injection to prevent HIV infection that could improve adherence ...

But don't forget that the U.S. does have an ongoing HIV epidemic, with approximately 36,801 people receiving an HIV diagnosis in the United States and dependent areas. HIV affects locations in the U.S ...